TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Imugene ( (AU:IMU) ) has shared an announcement.
Imugene Limited has announced its 2025 Annual General Meeting, which will address key business matters such as adopting the 2025 Remuneration Report, re-electing directors, and approving equity incentives. The company has made enhancements to its remuneration approach, emphasizing transparency and alignment with performance metrics, and the board intends to forego 50% of equity incentives as a gesture of confidence in challenging capital markets.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company operates in the competitive global biotech market, leveraging a US-centric executive remuneration framework to attract and retain specialized talent.
YTD Price Performance: -67.01%
Average Trading Volume: 2,983,825
Technical Sentiment Signal: Sell
Current Market Cap: A$122.8M
For detailed information about IMU stock, go to TipRanks’ Stock Analysis page.